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TB is now the leading, global cause of death due to a single infectiousmicrobe. To achieve the End TB vision of redu-
cing TB by 90% by 2035 we will need new interventions. The objectives of this manuscript are to summarize the
status of the clinical TB vaccine pipeline; to assess the challenges facing the TB development field; and to discuss
some of the key strategies being embraced by the field to overcome these challenges. Currently, 8 of the 13 vaccines
in clinical development are subunit vaccines; 6 of these contain or express either Ag85A or Ag85B proteins. A major
challenge to TB vaccine development is the lack of diversity in both the antigens included in TB vaccines, and the
immune responses elicited by TB vaccine candidates. Both will need to be expanded to maximise the potential
for developing a successful candidate by 2025. Current research efforts are focused on broadening both antigen
selection and the range of vaccine-mediated immune responses. Previous and ongoing TB vaccine efficacy trials
have built capacity, generated high quality data on TB incidence and prevalence, and provided insight into immune
correlates of risk of TB disease. These gainswill enable the design of better TB vaccines and, importantly, move these
vaccines into efficacy trials more rapidly and at a lower cost than was possible for previous TB vaccine candidates.
Keywords: BCG, Biomarker, T cell, Tuberculosis, Vaccine
Introduction
In 2014, TB became the leading, global cause of death due to a
single infectious disease.1 Globally there were 9.6 million new
cases and 1.5 million deaths in 2014. The greatest incidence of
TB disease is in sub-Saharan Africa, largely driven by the HIV
epidemic. To achieve the End TB vision of a 90% reduction in TB
incidence by 2035, we will need new interventions including
shorter, less toxic drug treatments, improved diagnostics and
more effective vaccines.2,3 It is estimated that with current bio-
medical interventions and improved social protection if fully
implemented, including global universal health coverage, we
can halve the current rate of TB cases from 100 to 50 per 100
000 per year by 2025. To reach the End TB vision of less than 10
per 100 000 by 2035, however, we will need new interventions
(Figure 1).
Vaccination is the most effective intervention for the control of
infectious disease. The eradication of smallpox and rinderpest and
the near eradication of polio have only been possible due to the
availability of highly effective vaccines. While the BCG vaccine,
first introduced in 1921, has been used worldwide to prevent
life-threatening TB disease in infants and children, it has demon-
strated limited and variable effectiveness in preventing pulmon-
ary TB and the transmission of Mycobacterium tuberculosis
(Mtb), the causal agent of TB, in adolescents and adults. The pos-
sibility of reaching the End TB vision of less than 10 cases per
100 000 per year in 2035 would be greatly enhanced if a more
effective vaccine for protection against the development of TB
disease in adolescents and adults, the prime sources of TB trans-
mission, were available by the year 2025.
An additional imperative to developing TB vaccines is the emer-
ging threat of drug-resistant Mtb strains; including multidrug-
resistant TB (MDR-TB), Mtb strains resistant to isoniazid and rifam-
pin, plus any fluoroquinolone and at least one of three injectable
second-line drug. Although the global incidence of MDR-TB
appears to be holding steady at approximately 3% of newly diag-
nosed TB cases, the devastating, debilitating, toxicity associated
with treating MDR-TB and extensively drug resistant TB (XDR-TB),
drug resistance of these types carry with them extraordinary eco-
nomic costs. The direct cost of treating MDR-TB and XDR-TB has
been found to be 8-fold and 25-fold higher, respectively, than
treating drug-sensitive TB.5 When considering the indirect cost
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of these diseases, including loss of productivity during convales-
cence, these costs rise to 15-fold and 35-fold the cost of drug-
sensitive TB, respectively. TB vaccines demonstrated to be effect-
ive against drug-sensitive strains should also be effective against
drug-resistant strains, as the nature of the drug-resistant muta-
tions would not be expected to change the immunological profile
of the organism. As there are no animal challenge models involv-
ing drug-resistant Mtb strains, given the danger of their use in
laboratory settings, the ultimate proof of this postulate will
need to be derived from clinical trials of vaccine with demon-
strated efficacy against drug-sensitive strains in populations
with an elevated incidence of Mtb drug-resistance.
The risk of failure of new TB vaccines in development is per-
ceived to be high due to both the complexity of the biology and
previous failure of a TB vaccine candidate in clinical testing.6,7
Due to the risk of failure and low commercial value, TB vaccine
development is unattractive to industry.6 The public health bene-
fits of an improved TB vaccine, however, would be high, and when
considered in a cost-benefit analysis investment in TB vaccine
development represents a cost-effective public health interven-
tion even if efficacy is only partial.8–10 Funders have responded
with renewed investment in TB vaccine development, resulting
in the 2014 launch of two major TB vaccine consortiums funded
through the Horizon 2020 EU Framework Programme for Research
and Innovation. In 2015 the Bill and Melinda Gates Foundation
and The European & Developing Countries Clinical Trials
Partnership (EDCTP) also committed funding for TB vaccine devel-
opment. The next few years should see a reinvigoration of the TB
vaccine development pipeline.
Current vaccines in clinical development
There are 13 vaccines currently in clinical development (self-
reported by vaccine sponsors). These can be divided into whole
cell-derived vaccines, viral vectored subunit vaccines and adju-
vanted protein subunit vaccines (see Supplementary file).
Whole cell-derived vaccines
The strategy of utilizing whole cell vaccines for TB has gained
increased interest due to the ongoing difficulties in identifying
individual antigens critical to generating protective immune
responses to Mtb. Additionally, as whole organisms, these vac-
cines induce a more diversified immune response than do
subunit-based vaccines, including both humoral and cellular
immune responses to a range of protein, lipid and antigens.
The candidate currently at the most advanced stage of clinical
trials isMycobacterium vaccae (VaccaeTM, AnHui Longcom Biologic
Pharmacy Co., Ltd [Longcom], Beijing, China), a non-TB mycobac-
teria (NTM) currently being assessed in a phase 3 trial for safety
and efficacy in preventing TB disease in purified protein derivative
(PPD) skin test positive adults in China.11 VaccaeTM already has
been licensed in China as an adjunct to therapy in persons with
TB disease.12 The phase 3 trial, in which the vaccine is adminis-
tered six times, has enrolled 10 000 subjects and is due for com-
pletion in mid-2016.
VPM1002 is the only recombinant BCG vaccine candidate cur-
rently in clinical trials. VPM1002 is designed to provide enhanced
immunogenicity as compared to BCG due to the insertion in
the BCG DNA of a gene for listeriolysin and the deletion of a urease
gene. This candidate, being developed by Vakzine Projekt
Management of Germany and the Serum Institute of India, is
being assessed as both a possible BCG replacement in infants
and as a vaccine to prevent recurrent TB disease in adults follow-
ing successful completion of treatment for active pulmonary TB. It
is also being developed as a replacement for BCG in the treatment
of bladder cancer.
MTBVAC represents the only whole cell candidate currently in
clinical trials that is derived from Mtb. Stable deletions of genes
Figure 1. The importance of new tools in achieving the End TB Strategy. The projected acceleration of TB incidence decline needed to reach the target of
the End TB Strategy.
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coding for two different Mtb virulence factors, phoP and fadD26,
have been made to ensure the safety of the vaccine. This vaccine,
being developed by investigators at the University of Zaragoza,
Spain, and BioFabri, primarily is being developed as a BCG replace-
ment vaccine in infants and is in phase 2 trials.
Like M. vaccae, DAR-901 is derived from a heat-inactivated
whole cell, NTM. When a heat-inactivated, agar-cultured prepar-
ation of this NTM was administered in multiple doses during a
phase 3 trial for prevention of disseminated TB disease in
HIV-infected participants (the DAR-DAR trial), significant protec-
tion against definite TB disease was observed (p¼0.03, 95% CI
0.39–0.96).13 Protection against disseminated disease was not
demonstrated, although the number of cases overall was small.
DAR-901, a broth-cultured preparation of this NTM, is being devel-
oped by investigators at Dartmouth University, USA, to prevent TB
disease in adolescents and adults. A phase 1 safety and immuno-
genicity trial recently was completed and a phase 2 trial in
Tanzania is being planned. The DAR-DAR trial, which included
HIV-infected participants, illustrates the importance of developing
vaccines both safe and effective for use in individuals at high-risk
for Mtb infection and TB disease.
RUTIw (Archivel Farma, Barcelona, Spain), developed by Dr.
Pere-Joan Cardona, Barcelona, Spain, consists of detoxified, frag-
mented Mtb contained in liposomes and comprises a range of
protein, lipid and glycolipid antigens. It is being developed as an
immunotherapeutic agent for use in persons with active TB to
reduce the extent and duration of drug treatment.
Although not currently being assessed clinically, a killed prep-
aration of Mycobacterium indicus pranii (Mip), a vaccine originally
used as a vaccine against leprosy, was demonstrated to have pro-
vided some protection against Mtb in a retrospective analysis of a
phase 3 leprosy trial.14 Plans for the further development of Mip,
however, are unclear.
Viral vectored vaccines
Ad5Ag85A, ChAdOx185A, MVA85A and TB/FLU-04Lare all viral vec-
tors expressing antigen 85A (Ag85A) from Mtb. Ag85A is a mycolyl
transferase enzyme important for cell wall synthesis. Ag85A is also
involved in lipid accumulation and storage, potentially important in
Mtb dormancy.15 The Ag85A protein is conserved across mycobac-
terial species including Mtb, BCG and environmental mycobacteria
and induces a strong Th1 type cellular immune response. Viral vec-
tors can induce high levels of Ag85A antigen specific CD4+ and
CD8+ T-cells in thosewith pre-exisiting immunity to Ag85A primed
by BCG vaccination or exposure to mycobacteria in the environ-
ment. TB/FLU-04L additionally contains ESAT-6, an immunodomi-
nant antigen secreted by Mtb but not BCG.
Adjuvanted protein subunit vaccines
M72+ AS01E, H4+ IC31, H1+ IC31, H56+ IC31 and ID93+
GLA-SE are adjuvanted protein subunit vaccines. These vaccines
are being developed as boosts to BCG to prevent de novo infection
with Mtb and/or reactivation in those already infected.
The Glaxo Smith Kline (GSK) product M72, a fusion protein con-
taining the Mtb genes MTB 32A and MTB 39A, in combination with
the GSK proprietary adjuvant AS01E, currently is the adjuvanted
protein subunit vaccine in themost advanced level of clinical test-
ing. An ongoing, phase 2b study of M72+ AS01E, cosponsored by
GSK and Aeras, is designed to assess the efficacy of this candidate
to prevent the development of active TB disease among persons
already infected with Mtb. Enrolement is complete and a total of
3573 adults have been enrolled in this study from South Africa,
Kenya and Zambia. Results from this study are expected in 2018.
The H4+ IC31 adjuvanted fusion protein vaccine candidate,
containing the Mtb antigens 85B and TB10.4, originally created
by SSI (Denmark) but now being developed by Sanofi Pasteur in
collaboration with Aeras, and administered in combination with
the Valneva IC31 adjuvant, currently is in a novel, phase 2 study
designed to assess the ability of this vaccine to prevent the estab-
lishment of Mtb infection in a cohort of South African adolescents
at high-risk of Mtb acquisition. The study, cosponsored by Aeras,
is fully enrolled; results are expected in 2017. Another IC31-
adjuvanted SSI vaccine candidate, H56, containing the Mtb anti-
gens 85B, ESAT6 and Rv2660c, is being assessed for safety and
immunogenicity in a phase 2 trial in South African adults.
ID93+ GLA-SE, developed by the Infectious Disease Research
Institute (IDRI), Seattle, USA, is composed of four Mtb antigens,
RV2608, Rv3619, Rv3620 and Rv1813, in combination with
IDRI’s proprietary adjuvant, GLA-SE. A phase 2 trial of the safety
and immunogenicity of the vaccine is ongoing.
Exploring new ideas in TB vaccine design
Broadening antigen selection
There is a dominance of vaccines that express contain Ag85 pro-
teins with six of the eight subunit vaccines containing an Ag85
protein (Ag85A or Ag85B). There is limited data from clinical effi-
cacy trials to determine whether a focus on this antigen or any
other individual antigen is an effective approach or not.
However, Mtb is a complex with a large number of protein, lipid
and glycolipid antigens that are known to be immunogenic in
humans. Induction of immunity across a broad range of mole-
cules is an alternative strategy to the highly focused subunit vac-
cine approach. As previously noted, the whole cell mycobacterial
vaccines DAR-901, VaccaeTM, VPM1002 and MTBVAC contain a
broader range of immunogenic molecules, as compared to viral
vectored and protein and adjuvant vaccines, and have the poten-
tial advantage of inducing a broader immune response.
Increasing the breadth of an immune response, however, fre-
quently has a cost of lowering the magnitude of the immune
response to any one individual antigen. Accordingly, strategies
that increase the breadth of immune response while maximizing
immune strength may be required.
Sequencing has shown that T-cell epitopes in almost all anti-
gens across different strains of Mtb are hyperconserved; across
1226 sequenced T-cell epitopes variation was only found in
seven genes.16,17 Hyperconservation indicates that the majority
of epitopes in Mtb are not under direct T-cell immune pressure.
This finding suggests that inclusion of one of the rare, variable
genes in a vaccine candidate may help to boost immunity to
one of the few antigens naturally exposed and pressured by a
T-cell immune response.
An alternative antigen selection strategy is to choose a con-
served antigen but redirect the immune response towards an epi-
tope within that antigen, which is either not usually recognized or
only weakly recognized during natural immunity. Such epitopes
are referred to as subdominant. The ability to induce immunity
and protection against challenge with Mtb subdominant epitopes
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has been demonstrated in mouse models.18–20 Translating this
approach to humans will require the identification and character-
ization of subdominant epitopes, a challenging task given the
extent of human leucocyte diversity as compared to epitope iden-
tification in less diverse, clonal mouse strains.
Broadening immune responses
We do not have a validated immune correlate of protection from
TB disease to aid the development of TB vaccine candidates.
However, the importance of Th1 type cellular immunity has
been demonstrated through human genetic studies and murine
Mtb challenge experiments;21–27 therefore, vaccines that focus
on the induction of a CD4+ and CD8+ Th1 type immune response
dominate the current TB vaccine pipeline. Although we have nei-
ther proved nor disproved the concept of Th1 type vaccine induced
immunity for protection against TB disease in clinical trials, it is
important to support the development of vaccines that enhance
further aspects of the immune response if we are to increase the
chances of obtaining a successful TB vaccine by 2025.
Humoral immunity
It is increasingly recognized that B cells and antibodies canmodu-
late the immune response to intracellular bacteria including
Mtb.28 Mechanisms of antibody-mediated protection are likely
to be both classical, including opsonization and complement acti-
vation, and non-classical, including modulation of immunity
through Fc receptor (FcR) engagement. FcRs can either inhibit or
activate immune responses, and inhibitory FcRs, such as FcYR
Y-chain, have been shown to limit immune pathology in active
TB disease.29 BCG can induce antibody, although only at modest
levels.30–33When pre-coated with sera from BCG vaccinated peo-
ple, however, the uptake of BCG by phagocytic cells is increased,
indicating that although modest in titre, BCG-induced antibodies
can have anti-mycobacterial effects.34 Designing vaccines to
boost antibody responses primed by the BCG vaccine is one strat-
egy open to TB vaccine developers, although care must be taken
to consider the pattern of FcR engagement of the boosted anti-
bodies. In addition, antibody avidity should be considered, given
the finding that, among patients with active TB, antibody was pre-
sent but avidity was lower than that of uninfected controls.35 It
will also be important to consider the impact of pre-existing anti-
body responses induced by environmental mycobacteria. A study
of non-BCG vaccinated UK school children found high titres of
mycobacterial specific IgG antibodies at birth and in older chil-
dren.36 Others have also found significant antibody responses
cross-reactive with NTM in healthy UK populations.37 The impact
of pre-existing responses on the immunogenicity and efficacy of
an antibody inducing vaccine should be assessed during clinical
development.
Non-classical T-cells
In recent years there have been new discoveries and greater
understanding of T-cells that do not express the classical T-cell
receptor, which recognises complexes of peptide antigen, in asso-
ciation with MHC molecules. Unconventional T-cells include CD1,
MR1, HLA-E and gd T-cells.38 These cells bear receptors able to
bind non-protein antigens and are present in large numbers in
the circulation and tissue, such as mucosa, making them capable
of reacting rapidly to infection. Innate lymphoid cells (ILCs) do not
bear any antigen receptor but react rapidly to inflammation
through cytokine receptors and secrete large quantities of cyto-
kine, which can shape the development of an adaptive immune
response.39 Natural killer (NK) cells can be considered a Type 1
ILC as they do not have an antigen receptor yet are quickly
recruited and secrete large quantities of IFN-g and cytotoxic
molecules following infection or vaccination.39,40
The subunit vaccines in the current TB vaccine pipeline are
designed to enhance classical T-cell responses against peptides
presented in association with MHC class I and II, respectively.
Innate lymphoid cells and unconventional T-cells such as NK
cells and gd T-cells, however, are induced by both BCG and viral vec-
tor vaccines in humans.41–45Current research is focused on optimal
antigen selection for enhancement of an unconventional T-cell
response relevant for long-term, vaccine-induced protection
against TB disease.
Vaccine design and the End TB strategy
There is a need for greater diversity in the antigens targeted and
immune responses elicited by TB vaccine candidates if we are to
maximize our chances of obtaining a successful candidate by
2025. In recognition of this, there has been renewed investment
in TB vaccine development by funders, such as the EU Horizon
2020 Programme and the Bill and Melinda Gates Foundation.
These funders have specifically encouraged the development of
TB vaccine candidates that would broaden the current vaccine
portfolio to include mucosal immunity inducing, antibody indu-
cing, and non-conventional T-cell inducing vaccines.46
TB vaccine clinical trials and the End TB
Strategy
There are ongoing VaccaeTM, VPM1002, M72+ AS01E and H4+
IC31 TB vaccine efficacy trials. Even if these vaccines do not dem-
onstrate sufficient efficacy to merit further development, con-
ducting these and other later stage clinical trials will hasten the
development of a TB vaccine that ultimately will prove to be suc-
cessful. Direct results of conducting later stage clinical trials
include building capacity; generating high quality data on TB inci-
dence and prevalence; gathering data on TB vaccine safety; gain-
ing insight into immune correlates of risk of TB disease. Also, if
conducted in parallel with properly designed NHP or other animal
model studies, will help determine if the animal model is predict-
ive. Even vaccines that showed very limited efficacy have potential
to be used to identify correlates of protection.
These gains will enable us to design better TB vaccines and,
importantly, to move these vaccines into advanced efficacy trials
more rapidly and at lower cost than was possible for previous TB
vaccine candidates.
Impact of host-immunity on vaccine response
Factors specific to the host can impact on the response to a vac-
cine and may interfere with vaccine efficacy. Coinfection with
pathogens is one factor known to modulate the immune
response.47 TB vaccine trial participants are therefore screened
for symptomatic evidence of active infection and specifically
Transactions of the Royal Society of Tropical Medicine and Hygiene
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screened for infection with HIV and hepatitis B virus (HBV). For
some infections, such as cytomegalovirus (CMV) and influenza,
however, the immune response may be altered for substantial
periods of time after symptoms are no longer apparent and
could impact on vaccine immunogenicity and efficacy in clinical
trials.48–50 Gene signatures associated with a Type 1 interferon
immune response are increased in those at risk of progressing
to TB disease (Zak, Penn-Nicholson, Scriba et al; Forthcoming)
and increased frequencies of monocytes relative to lymphocytes
have been associated with risk of progression to TB disease.51–53
How these and other factors could impact TB vaccine efficacy
have not been determined but care should be taken to collect
data on cofactors during clinical efficacy trials.
Vaccines and social interventions: working
together to End TB
There is no doubt that TB transmission and progression are driven
by social factors, including crowded, poorly ventilated housing,
transportation and classrooms in areas where TB is otherwise
endemic, and exogenous situations that increase a person’s sus-
ceptibility to Mtb infection and TB disease, such as poor nutrition.
Addressing the socioeconomic determinants of TB disease are
necessary components in any comprehensive strategy designed
to contain the global TB epidemic.54 Unfortunately, the case for
social interventions is sometimes presented as an alternative to
investment in TB vaccine development. It is critical that these
complementary strategies not be viewed from the perspective
of a ‘zero-sum game’: furtherance of both approaches will be
imperative for a strategy to end the global TB epidemic to suc-
ceed. As noted in the Stop TB Strategy, TB vaccine research and
development efforts are vastly underfunded, with an annual
funding shortfall of approximately US$250 million.55 Clearly, fur-
ther depleting TB vaccine R&D funding, even in support of other-
wise well-intentioned TB control initiatives, would be
short-sighted and would have a devastating effect on the TB vac-
cine development effort.
Conclusions
Developing new vaccines capable of preventing active TB disease
and thereby decreasing Mtb transmission represents a critical
strategy in the overall efforts to end the global TB epidemic.
Although the current TB vaccine clinical pipeline contains a degree
of diversity in terms of vaccine delivery platforms, ranging from
whole mycobacterial cell vaccines to adjuvanted proteins and
vectored vaccines, these candidates generate CD4+ and, to a
lesser extent, CD8+ T-cell responses. Clearly, there is a need to
develop greater immunologic diversity in the current TB vaccine
pipeline. In recognition of this, funders have invested in TB vaccine
development with a particular focus on efforts to induce uncon-
ventional T-cell responses (e.g. CD1, MR1, HLA-E and gd T-cells)
and antibody responses to broaden vaccine immunogenicity. By
conducting later stage clinical trials, which include preliminary
assessments of efficacy, we have built research capacity, gener-
ated high quality data on TB incidence and prevalence, and gained
insight into immune correlates of risk of TB disease. These gains
will enable the design of better TB vaccines and the acceleration
of the move into efficacy trials more rapidly than was possible for
previous TB vaccine candidates. Further investment is needed to
enable the conduct of additional, robust trials of TB vaccine safety,
immunogenicity and efficacy. Potential cofactors, such as dia-
betes mellitus and malnutrition, have been identified which
could impact TB disease risk and vaccine efficacy. These cofactors
should be assessed during efficacy trials of TB vaccines.
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(http://trstmh.oxfordjournals.org/).
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